This analysis examines the historical and forecast performance for GlaxoSmithKline in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
* Gain insight into GlaxoSmithKline's strategic outlook across the next 6 years.* Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source.
Highlights
Strategic insight into the prospects for GlaxoSmithKline over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
* Benchmark GlaxoSmithKline's performance against key rivals in the prescription pharmaceutical sector* Assess GlaxoSmithKline's continued diversification strategy with vaccines and emerging markets positioned as key growth opportunities.*
------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/
------------------------------------------------------------
Partial Table of Contents:
TABLE OF CONTENTS
ABOUT DATAMONITOR HEALTHCARE
About the PharmaVitae team
Chapter 1 About this profile
PharmaVitae Explorer database
Chapter structure
Data sourcing
Chapter 2 Executive summary
Key findings
Prescription pharmaceutical sales and growth rate performance, 2003-15
Financial performance, 2003-15
GlaxoSmithKline:
Strategic insight
SWOT analysis
Chapter 3 Quarterly news update
Latest quarterly sales
Latest quarterly financial analysis
Latest comment
Latest prescription pharma product news
Latest corporate news
Future product milestones
Chapter 4 Company introduction
Key findings
Background
M&A history
Chapter 5 Company sales
Key findings
Prescription pharmaceutical sales and growth rate analysis, 2003-15
Product analysis
Therapy area analysis
Geographic analysis
Launch/core/
Molecule type analysis
Externalization analysis
Chapter 6 Company financials
Key findings
Reconciliation between PharmaVitae-
Operating costs and profit analysis
Chapter 7 Key products
Overview
Chapter 8 Appendix
References
Abbreviations
Exchange rates
About Datamonitor
Datamonitor consulting
Disclaimer
TABLE OF TABLES
Table 1: GlaxoSmithKline - PharmaVitae forecasts at a glance
Table 2: GlaxoSmithKline quarterly sales ($m), Q309-Q310
Table 3: GlaxoSmithKline quarterly financials ($m), Q309-Q310
Table 4: GlaxoSmithKline future product milestones, 2010-12
Table 5: GlaxoSmithKline product portfolio overview ($m), 2003-09
Table 6: GlaxoSmithKline product portfolio overview ($m), 2009-15
Table 7: GlaxoSmithKline prescription pharmaceutical sales by therapy area ($m), 2009-15
Table 8: GlaxoSmithKline prescription pharmaceutical sales by geographic region ($m), 2009-15
Table 9: GlaxoSmithKline launch portfolio overview ($m), 2009-15
Table 10: GlaxoSmithKline core portfolio overview ($m), 2009-15
Table 11: GlaxoSmithKline expiry portfolio overview ($m), 2009-15
Table 12: GlaxoSmithKline prescription pharmaceutical sales by molecule type ($m), 2009-15
Table 13: GlaxoSmithKline vaccine sales ($m), 2008-14
Table 14: GlaxoSmithKline prescription pharmaceutical sales by source ($m), 2009-15
Table 15: Total GlaxoSmithKline sales by business unit ($m), 2003-09
Table 16: GlaxoSmithKline operating revenue/cost analysis ($m), 2003-09
Table 17: GlaxoSmithKline operating cost ratio analysis (% of total revenues), 2003-09
Table 18: GlaxoSmithKline operating cost ratio analysis (% of total revenues), 2009-15
Table 19: GlaxoSmithKline operating revenue/cost analysis ($m), 2009-15
Table 20: GlaxoSmithKline Key products overview
Table 21: Beyond Advair: overview
Table 22: Beyond Advair: sales forecast ($m), 2009-15
Table 23: Duodart: overview
Table 24: Duodart: sales forecast ($m), 2009-15
Table 25: Almorexant: overview
Table 26: Almorexant: sales forecast ($m), 2009-15
Table 27: Tykerb/Tyverb:
Table 28: Tykerb/Tyverb:
Table 29: Synflorix: overview
Table 30: Synflorix: sales forecast ($m), 2009-15
Table 31: Valtrex: overview
Table 32: Valtrex: sales forecast ($m), 2009-15
Table 33: Seretide/Advair:
Table 34: Seretide/Advair:
Table 35: Influenza Vaccines: overview
Table 36: Influenza Vaccines: sales forecast ($m), 2009-15
Table 37: Flixotide/Flovent:
Table 38: Flixotide/Flovent:
Table 39: Avandia: overview
Table 40: Avandia: sales forecast ($m), 2009-15
Table 41: Exchange rates, 2010
TABLE OF FIGURES
Figure 1: The PharmaVitae Explorer
Figure 2: GlaxoSmithKline prescription pharmaceutical performance, sales ($m) and growth rate (%), 2003-15
Figure 3: GlaxoSmithKline's financial performance ($m), 2003-15
Figure 4: GlaxoSmithKline launch/core/
Figure 5: GlaxoSmithKline launch/core/
Figure 6: GlaxoSmithKline SWOT analysis
Figure 7: M&A/divestment history
Full Table of Contents is available at:
-- http://www.fastmr.com/
About Datamonitor
The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at http://www.fastmr.com/
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
# # #
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
